Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
BACKGROUND
Anxiety, depression, and impaired health-related quality of life (HRQoL) are common in patients with psoriasis.


OBJECTIVE
We sought to analyze the effect of ustekinumab on these conditions in patients with moderate-to-severe psoriasis.


METHODS
Patients with moderate-to-severe psoriasis (n = 1230) were randomized 1:1:1 to receive 45 mg of ustekinumab, 90 mg of ustekinumab, or placebo. The Hospital Anxiety and Depression Scale was used to measure anxiety and depression, and the Dermatology Life Quality Index to measure HRQoL.


RESULTS
At baseline, 40.3% and 26.7% of patients reported symptoms of anxiety and depression, respectively, and 54.6% reported Dermatology Life Quality Index scores greater than 10, indicating a very high impact of disease on HRQoL. Greater improvements at week 12 in mean Hospital Anxiety and Depression Scale-Anxiety (13.9%), Hospital Anxiety and Depression Scale-Depression (29.3%), and Dermatology Life Quality Index (76.2%) scores were reported in ustekinumab groups compared with placebo (P < .001 each).


CONCLUSIONS
Results for these measures are reported only through 24 weeks.


CONCLUSIONS
Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL.
Langley
Richard G
RG
Dalhousie University, Halifax, Nova Scotia, Canada.
Feldman
Steven R
SR
Han
Chenglong
C
Schenkel
Brad
B
Szapary
Philippe
P
Hsu
Ming-Chun
MC
Ortonne
Jean-Paul
JP
Gordon
Kenneth B
KB
Kimball
Alexa B
AB
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D001007:Anxiety / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology*; D011788:Quality of Life; D012016:Reference Values; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab